vs
Essex Property Trust（ESS）とPrestige Consumer Healthcare Inc.（PBH）の財務データ比較。上の社名をクリックして会社を切り替えられます
Essex Property Trustの直近四半期売上が大きい（$479.6M vs $283.4M、Prestige Consumer Healthcare Inc.の約1.7倍）。Essex Property Trustの純利益率が高く（17.9% vs 16.5%、差は1.4%）。Essex Property Trustの前年同期比売上増加率が高い（5.5% vs -2.4%）。過去8四半期でEssex Property Trustの売上複合成長率が高い（6.0% vs 1.2%）
Essex Property Trustは上場不動産投資信託で、主にアメリカ合衆国カリフォルニア州及びシアトル大都市圏のアパートメント物件への投資を中核事業としており、賃貸住宅の投資、運用、管理分野で豊富な実績とリソース優位性を持っています。
プレステージ・コンシューマー・ヘルスケア社はアメリカの企業で、一般用医薬品のヘルスケア製品および家庭用洗浄製品の販売・流通を手がけています。1996年にMedtech Products社、Prestige Brands International社、Spic and Span社の合併により設立され、本社はニューヨーク州タリータウン、バージニア州リンチバーグに製造工場を構えています。
ESS vs PBH — 直接比較
損益計算書 — Q4 FY2025 vs Q3 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $479.6M | $283.4M |
| 純利益 | $85.7M | $46.7M |
| 粗利率 | 70.0% | 55.5% |
| 営業利益率 | 31.7% | 29.1% |
| 純利益率 | 17.9% | 16.5% |
| 売上前年比 | 5.5% | -2.4% |
| 純利益前年比 | -71.6% | -23.5% |
| EPS（希薄化後） | $1.24 | $0.97 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $479.6M | $283.4M | ||
| Q3 25 | $473.3M | $274.1M | ||
| Q2 25 | $469.8M | $249.5M | ||
| Q1 25 | $464.6M | $296.5M | ||
| Q4 24 | $454.5M | $290.3M | ||
| Q3 24 | $450.7M | $283.8M | ||
| Q2 24 | $442.4M | $267.1M | ||
| Q1 24 | $426.9M | $277.0M |
| Q4 25 | $85.7M | $46.7M | ||
| Q3 25 | $172.7M | $42.2M | ||
| Q2 25 | $231.5M | $47.5M | ||
| Q1 25 | $212.8M | $50.1M | ||
| Q4 24 | $301.7M | $61.0M | ||
| Q3 24 | $125.5M | $54.4M | ||
| Q2 24 | $99.0M | $49.1M | ||
| Q1 24 | $285.1M | $49.5M |
| Q4 25 | 70.0% | 55.5% | ||
| Q3 25 | 69.2% | 55.3% | ||
| Q2 25 | 70.7% | 56.2% | ||
| Q1 25 | 69.6% | 57.3% | ||
| Q4 24 | 70.0% | 55.5% | ||
| Q3 24 | 69.5% | 55.5% | ||
| Q2 24 | 70.8% | 54.7% | ||
| Q1 24 | 69.7% | 54.8% |
| Q4 25 | 31.7% | 29.1% | ||
| Q3 25 | 44.5% | 29.1% | ||
| Q2 25 | 59.5% | 28.8% | ||
| Q1 25 | 55.3% | 29.8% | ||
| Q4 24 | 67.0% | 31.7% | ||
| Q3 24 | 28.6% | 29.7% | ||
| Q2 24 | 31.1% | 27.0% | ||
| Q1 24 | 31.0% | 29.7% |
| Q4 25 | 17.9% | 16.5% | ||
| Q3 25 | 36.5% | 15.4% | ||
| Q2 25 | 49.3% | 19.0% | ||
| Q1 25 | 45.8% | 16.9% | ||
| Q4 24 | 66.4% | 21.0% | ||
| Q3 24 | 27.8% | 19.2% | ||
| Q2 24 | 22.4% | 18.4% | ||
| Q1 24 | 66.8% | 17.9% |
| Q4 25 | $1.24 | $0.97 | ||
| Q3 25 | $2.56 | $0.86 | ||
| Q2 25 | $3.44 | $0.95 | ||
| Q1 25 | $3.16 | $1.00 | ||
| Q4 24 | $4.00 | $1.22 | ||
| Q3 24 | $1.84 | $1.09 | ||
| Q2 24 | $1.45 | $0.98 | ||
| Q1 24 | $4.25 | $0.98 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $76.2M | $62.4M |
| 総負債低いほど良い | — | $1.0B |
| 株主資本純資産 | $5.5B | $1.8B |
| 総資産 | $13.2B | $3.5B |
| 負債/資本比率低いほどレバレッジが低い | — | 0.56× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $76.2M | $62.4M | ||
| Q3 25 | $66.0M | $119.1M | ||
| Q2 25 | $58.7M | $139.5M | ||
| Q1 25 | $98.7M | $97.9M | ||
| Q4 24 | $66.8M | $50.9M | ||
| Q3 24 | $71.3M | $51.5M | ||
| Q2 24 | $55.2M | $34.3M | ||
| Q1 24 | $499.0M | $46.5M |
| Q4 25 | — | $1.0B | ||
| Q3 25 | $6.4B | $993.1M | ||
| Q2 25 | $6.4B | $992.7M | ||
| Q1 25 | $6.8B | $992.4M | ||
| Q4 24 | — | $992.0M | ||
| Q3 24 | $6.4B | $1.1B | ||
| Q2 24 | $6.2B | $1.1B | ||
| Q1 24 | $6.6B | $1.1B |
| Q4 25 | $5.5B | $1.8B | ||
| Q3 25 | $5.6B | $1.8B | ||
| Q2 25 | $5.6B | $1.9B | ||
| Q1 25 | $5.6B | $1.8B | ||
| Q4 24 | $5.5B | $1.8B | ||
| Q3 24 | $5.4B | $1.7B | ||
| Q2 24 | $5.5B | $1.7B | ||
| Q1 24 | $5.5B | $1.7B |
| Q4 25 | $13.2B | $3.5B | ||
| Q3 25 | $13.2B | $3.4B | ||
| Q2 25 | $13.2B | $3.4B | ||
| Q1 25 | $13.2B | $3.4B | ||
| Q4 24 | $12.9B | $3.3B | ||
| Q3 24 | $12.6B | $3.3B | ||
| Q2 24 | $12.5B | $3.3B | ||
| Q1 24 | $12.9B | $3.3B |
| Q4 25 | — | 0.56× | ||
| Q3 25 | 1.15× | 0.54× | ||
| Q2 25 | 1.14× | 0.54× | ||
| Q1 25 | 1.22× | 0.54× | ||
| Q4 24 | — | 0.55× | ||
| Q3 24 | 1.18× | 0.61× | ||
| Q2 24 | 1.13× | 0.65× | ||
| Q1 24 | 1.19× | 0.68× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $1.1B | $78.3M |
| フリーキャッシュフロー営業CF - 設備投資 | — | $75.3M |
| FCFマージンFCF / 売上 | — | 26.6% |
| 設備投資強度設備投資 / 売上 | — | 1.1% |
| キャッシュ転換率営業CF / 純利益 | 12.53× | 1.68× |
| 直近12ヶ月FCF直近4四半期 | — | $267.2M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $1.1B | $78.3M | ||
| Q3 25 | $342.6M | $57.5M | ||
| Q2 25 | $216.1M | $79.0M | ||
| Q1 25 | $281.5M | $61.8M | ||
| Q4 24 | $1.1B | $65.1M | ||
| Q3 24 | $316.2M | $69.8M | ||
| Q2 24 | $218.9M | $54.8M | ||
| Q1 24 | $314.9M | $66.9M |
| Q4 25 | — | $75.3M | ||
| Q3 25 | — | $55.4M | ||
| Q2 25 | — | $78.2M | ||
| Q1 25 | — | $58.4M | ||
| Q4 24 | — | $63.5M | ||
| Q3 24 | — | $67.8M | ||
| Q2 24 | — | $53.6M | ||
| Q1 24 | — | $63.8M |
| Q4 25 | — | 26.6% | ||
| Q3 25 | — | 20.2% | ||
| Q2 25 | — | 31.3% | ||
| Q1 25 | — | 19.7% | ||
| Q4 24 | — | 21.9% | ||
| Q3 24 | — | 23.9% | ||
| Q2 24 | — | 20.1% | ||
| Q1 24 | — | 23.0% |
| Q4 25 | — | 1.1% | ||
| Q3 25 | — | 0.8% | ||
| Q2 25 | — | 0.3% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | — | 0.5% | ||
| Q3 24 | — | 0.7% | ||
| Q2 24 | — | 0.4% | ||
| Q1 24 | — | 1.1% |
| Q4 25 | 12.53× | 1.68× | ||
| Q3 25 | 1.98× | 1.36× | ||
| Q2 25 | 0.93× | 1.66× | ||
| Q1 25 | 1.32× | 1.23× | ||
| Q4 24 | 3.54× | 1.07× | ||
| Q3 24 | 2.52× | 1.28× | ||
| Q2 24 | 2.21× | 1.12× | ||
| Q1 24 | 1.10× | 1.35× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
ESS
セグメントデータなし
PBH
| Womens Health | $51.8M | 18% |
| International OTC Healthcare | $47.7M | 17% |
| Gastrointestinal | $44.2M | 16% |
| Eye And Ear Care | $35.2M | 12% |
| Dermatologicals | $27.6M | 10% |
| Analgesics | $26.7M | 9% |
| Oral Care | $23.5M | 8% |
| Cough And Cold | $23.0M | 8% |
| Other Otc | $3.6M | 1% |
